Navigation Links
Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
Date:12/13/2007

he time or in the manner Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications

Arena Pharmaceuticals, Inc.

858.453.7200, ext. 1682


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... San Diego, CA (PRWEB) December 17, 2014 ... strategy and activation agency and member of the Huntsworth ... Jamie Gonzales to its executive team. In her role, ... Services. , “We are incredibly honored to welcome ... said Agency Chief and CEO, Gaëtan Fraikin. “She is ...
(Date:12/17/2014)... Md. , Dec. 17, 2014  United Therapeutics ... senior executive promotions as well as changes to ... Senior Executive Promotions United Therapeutics announced ... President and Co-Chief Executive Officer and David Zaccardelli ... Officer.  In connection with these promotions, Dr. Rothblatt,s title ...
(Date:12/17/2014)... Dec. 17, 2014 Tigercat Pharma, Inc. ... study evaluating the investigational oral NK-1 receptor antagonist ... severe, chronic itch who are unresponsive or inadequately ... topical steroids and antihistamines. The ... Analog Scale (VAS) itch score from baseline, comparing ...
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce that ... with PVM technology , is now available. The ... tool continuously captures high-resolution images under a wide ... prepares a report pairing the most relevant images ... This compelling blend of high resolution images and ...
Breaking Biology Technology:Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
... , GENEVA, Sept. 11 Friendly LRL Holdings ... tender offer to acquire all of the outstanding shares of ... ("Startech"), effective immediately. FLH,s offer was scheduled to expire ... 30, 2009. All shares previously tendered pursuant to the ...
... , , NEW YORK, Sept. 10 ... Executive Officer Dr. Allan E. Rubenstein will be presenting at two ... will take place on September 11th, 2009 at 11:40am as part ... York, New York. The second presentation will take place on ...
... , WALTHAM, Mass. and CLEARWATER, Fla., ... Corporation, a leading developer of whole blood analyzers, and ... supplies, today announced that they have reached a definitive ... Sanvita CBGM, LLC, will acquire certain assets of Sanvita, ...
Cached Biology Technology:Friendly LRL Holdings Terminates Offer To Acquire Startech Environmental Corporation 2Friendly LRL Holdings Terminates Offer To Acquire Startech Environmental Corporation 3NexGenix Pharmaceuticals to Present at Two Industry Conferences: Rodman & Renshaw 11th Annual Healthcare Conference and Life Sciences Summit 2009 2Nova Biomedical and CCS Medical Reach Definitive Agreement for a Subsidiary of Nova Biomedical to Acquire Assets of CCS Medical's Subsidiary, Sanvita Inc. 2Nova Biomedical and CCS Medical Reach Definitive Agreement for a Subsidiary of Nova Biomedical to Acquire Assets of CCS Medical's Subsidiary, Sanvita Inc. 3
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: ... but can,t remember your password, site key or the answer ... your first grade teacher? Today, Hoyos ... app that will finally put an end to the ... 1U TM . 1U leverages a user,s smartphone to ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... Iowa Antiviral drugs block influenza A viruses from reproducing ... channel necessary for the virus to infect healthy cells, according ... Hong and published in the Feb. 4 issue of the ... Corbett Professor of Chemistry and an associate scientist for the ...
... N.J. , Feb. 3 Zymes LLC is pleased to ... be sampled at the NFL Alumni,s Super Bowl XLIV Weekend events on ... of OmegaChill at Super Bowl XLIV Weekend events along with ... health will serve as keynotes to Zymes LLC,s launch of OmegaChill ...
... Researchers at North Carolina State University have developed a "smart ... and ward off infection. When patients have hip, knee ... their bodies reject the implant. But the smart coating developed ... into the implant. The coating creates a crystalline layer next ...
Cached Biology News:Iowa State, Ames Lab chemists discover how antiviral drugs bind to and block flu virus 2Zymes LLC's Omega-3 Enhanced Water OmegaChill to be Distributed at NFL Alumni Super Bowl XLIV Weekend Events on February 5-7th, 2010 2Smart coating opens door to safer hip, knee and dental implants 2
Human IL-19 MAb (Clone 152112)...
SRY (sex determining region Y)-box 10...
... Stainless Steel Staining tray 19 x ... gel staining and blot processing.Automated staining of ... and nucleic acid analysis. Prepares blots for ... Programmable control of protocol, solution, volume, and ...
One-step, microplate or cuvet, colorimetric, linear detection range 0.1 mg/dL to 100 mg/dL. Procedure: 20 min....
Biology Products: